US · BRKRP
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Billerica, MA 01821
- Website
- bruker.com
Price · as of 2024-12-31
$292.49
Market cap 48.79B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | $2.59 | -99.11% |
| Graham Formula(GF) | $16.05 | -94.51% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $5.50 | $14.15 | |||
| 2011 | $5.96 | $18.74 | |||
| 2012 | $5.89 | $7.55 | |||
| 2013 | $6.75 | $5.11 | |||
| 2014 | $5.53 | $2.23 | |||
| 2015 | $6.60 | $0.00 | |||
| 2016 | $5.85 | $7.01 | |||
| 2017 | $3.64 | $8.61 | |||
| 2018 | $7.37 | $17.50 | |||
| 2019 | $7.96 | $21.75 | |||
| 2020 | $7.01 | $4.23 | |||
| 2021 | $11.68 | $52.70 | |||
| 2022 | $11.47 | $25.01 | |||
| 2023 | $17.00 | $71.73 | |||
| 2024 | $2.59 | $16.05 |
AI valuation
Our deep-learning model estimates Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A's (BRKRP) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $292.49
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
$2.59
-99.11% upside
Graham Formula
$16.05
-94.51% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BRKRP | Bruker Corporation 6.375%… | $292.49 | 48.79B | — | — | -99% | -95% | — | — | — | — | — | — | 49.00% | 7.52% | 3.36% | 7.21% | 4.59% | 2.26% | 1.26 | 5.28 | 1.60 | 0.58 | 4.70 | -7379.00% | 1356.00% | -4408.00% | — | 0.20 | 4.45% | — | 26.50% | — | — | — | — | — |
| A | Agilent Technologies, Inc… | $146.77 | 41.61B | -35% | -57% | -89% | -54% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $74.34 | 36.75B | -20% | -54% | -59% | -66% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| ARGX | argenx SE | $832.35 | 50.91B | -57% | +3,463% | -81% | +39% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| CAH | Cardinal Health, Inc. | $196.79 | 46.76B | -43% | +157% | — | -79% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| EW | Edwards Lifesciences Corp… | $82.84 | 48.64B | -2% | -53% | -71% | -57% | 47.67 | 4.93 | 8.40 | 33.68 | — | 6.85 | 78.13% | 26.97% | 17.69% | 10.52% | 19.08% | 7.99% | 0.01 | — | 3.72 | 2.12 | -1.98 | -7374.00% | 1155.00% | 36050.00% | 2.62% | 0.88 | 18.76% | 0.00% | 0.00% | 2.71% | 29.43 | 36.07 | 7.94 | 11.83 |
| HLN | Haleon plc | $9.31 | 42.18B | +324% | -45% | — | -77% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| IDXX | IDEXX Laboratories, Inc. | $720.21 | 57.51B | -40% | -46% | -89% | -67% | 48.13 | 31.77 | 11.85 | 35.33 | 213.11 | 47.15 | 61.80% | 31.60% | 24.62% | 66.20% | 45.37% | 31.89% | 0.67 | 35.54 | 1.17 | 0.76 | 0.61 | 2259.00% | 1042.00% | 3199.00% | 2.07% | 1.03 | 43.92% | 0.00% | 0.00% | 2.39% | 38.16 | 49.26 | 12.06 | 22.89 |
| RMD | ResMed Inc. | $245.22 | 35.94B | -6% | -37% | -85% | -32% | 28.88 | 6.78 | 7.86 | 20.96 | 77.17 | 16.47 | 59.36% | 32.75% | 27.22% | 25.86% | 25.33% | 18.62% | 0.14 | 133.66 | 3.44 | 2.16 | -0.19 | 3743.00% | 984.00% | 2918.00% | 4.11% | 1.72 | 29.91% | 0.77% | 22.20% | 3.96% | 23.79 | 24.13 | 7.79 | 13.72 |
| TAK | Takeda Pharmaceutical Com… | $13.59 | 42.85B | +67% | -56% | — | -75% | 66.53 | 1.04 | 1.57 | 9.33 | — | -3.55 | 65.51% | 7.48% | 2.36% | 1.52% | 1.87% | 0.74% | 0.65 | 2.49 | 1.01 | 0.45 | 3.41 | -2624.00% | 745.00% | 26347.00% | 11.93% | 0.42 | 7.55% | 4.21% | 280.30% | 8.50% | 32.96 | 13.18 | 2.46 | 1.11 |
| VEEV | Veeva Systems Inc. | $295.26 | 48.4B | -37% | -31% | -81% | -65% | 49.42 | 6.05 | 12.85 | 41.34 | 144.65 | 6.60 | 74.53% | 25.17% | 26.00% | 13.63% | 75.08% | 10.78% | 0.01 | — | 4.51 | 4.44 | -1.43 | 3416.00% | 1620.00% | 2083.00% | 3.03% | 0.78 | 149.51% | 0.00% | 0.00% | 1.12% | 43.70 | 28.25 | 11.00 | 16.19 |
About Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.
- CEO
- Frank H. Laukien
- Employees
- 11.4K
- Beta
- 1.26
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $292.49) − 1 = — (DCF, example).